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Abstract
Foetal/neonatal alloimmune thrombocytopaenia (NAIT) results from maternal alloimmunisation
against foetal platelet antigens inherited from the father and different from those present in the
mother, and usually presents as a severe isolated thrombocytopaenia in otherwise healthy
newborns. The incidence has been estimated at 1/800 to 1/1 000 live births. NAIT has been
considered to be the platelet counterpart of Rh Haemolytic Disease of the Newborn (RHD).
Unlike RHD, NAIT can occur during a first pregnancy. The spectrum of the disease may range from
sub-clinical moderate thrombocytopaenia to life-threatening bleeding in the neonatal period. Mildly
affected infants may be asymptomatic. In those with severe thrombocytopaenia, the most common
presentations are petechiae, purpura or cephalohaematoma at birth, associated with major risk of
intracranial haemorrhage (up to 20% of reported cases), which leads to death or neurological
sequelae. Alloimmune thrombocytopaenia is more often unexpected and is usually diagnosed after
birth. Once suspected, the diagnosis is confirmed by demonstration of maternal antiplatelet
alloantibodies directed against a paternal antigen inherited by the foetus/neonate. Post-natal
management involves transfusion of platelets devoid of this antigen, and should not be delayed by
biological confirmation of the diagnosis (once the diagnosis is suspected), especially in case of
severe thrombocytopaenia. Prompt diagnosis and treatment are essential to reduce the chances of
death and disability due to haemorrhage. Due to the high rate of recurrence and increased severity
of the foetal thrombocytopaenia in successive pregnancies, antenatal therapy should be offered.
However, management of high-risk pregnancies is still a matter of discussion.
Disease name/synonyms
Foetal/neonatal alloimmune thrombocytopenia (FAIT/
NAIT) [1] or foeto-maternal alloimmunisation thrombo-
cytopenia (FMAIT) [2].
Definition/diagnostic criteria
Foetal/neonatal alloimmune thrombocytopaenia (NAIT)
is a disorder caused by foetomaternal platelet incompati-
bility that usually presents as severe isolated thrombocy-
topaenia in otherwise healthy newborns. It results from
destruction of the foetal platelets by maternal immu-
noglobulin G (IgG) antibodies elicited during pregnancy
and directed against foetus-specific platelet antigens that
are inherited from the father and are different from those
present in the mother [1].
Clinically, the diagnosis is suspected when an otherwise
healthy neonate, born after an uneventful pregnancy and
delivery, exhibits petechiae or widespread purpura at birth
or a few hours after birth. Visceral haemorrhages are less
common. The mother is typically healthy, with no previ-
ous history of thrombocytopaenia, auto-immune disor-
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ders or ingestion of drugs. The infant has no clinical signs
of infection or malformations (see Differential diagnosis).
Approximately 20% of these infants show evidence of
intracranial haemorrhage (ICH) leading to death or neu-
rological sequelae (see Prognosis). The platelet count is
low at birth and may be associated with anaemia, second-
ary to bleeding. Platelet immunological investigations
will confirm the maternal specific alloimmunisation (see
Diagnostic methods).
Epidemiology
NAIT is the commonest cause of severe isolated thrombo-
cytopaenia in the foetus and newborn. Prospective studies
showed that it occurs in about 1 in 800 or 1000 live births
[3,4]. Unselected cohort of neonates reported 0.9% fre-
quency of neonatal thrombocytopaenia [5]. Immune aeti-
ology was demonstrated in one third of these cases. As
thrombocytopaenia when moderate (whatever its cause)
is often silent, systematic neonatal blood sampling for a
platelet count is the only possible way to detect neonatal
thrombocytopaenia and to provide better management of
the infant and subsequent pregnancies [5].
Clinical description
In the foetus, alloimmune thrombocytopaenia is consid-
ered to be the most severe thrombocytopaenia. It may
occur very early during pregnancy, and in several studies,
ICH has been documented before 20 weeks of gestation
[6-8]. In utero, ICH accounts for approximately 50% of
the reported cases of ICH in NAIT. Therefore, NAIT should
be considered as a potential aetiological factor in all cases
where porencephaly, ventriculomegaly and, in fact, any
type of ICH is discovered during the foetal life.
In the neonate, purpura or haematoma are the most com-
mon clinical manifestations. Visceral haemorrhages, such
as gastrointestinal bleeding or haematuria, occur less fre-
quently. ICH has been reported in NAIT (whatever the
platelet antigen involved, see Aetiology) and is usually
present at birth. ICH may also occur later, if the thrombo-
cytopaenia persists. Mildly affected infants may be asymp-
tomatic.
Anti HPA-1a and -3a immunisation induce severe neona-
tal thrombocytopaenia (see Aetiology) [9]. NAIT linked to
HPA-5b incompatibility seems to be less severe than HPA-
1a NAIT [10]. However, the infant may be symptomless,
with thrombocytopaenia discovered incidentally, even in
case of HPA-1a alloimmunisation. Therefore, unexpected
or unexplained neonatal thrombocytopaenia or early
onset of severe thrombocytopaenia in both pre-term and
term babies should raise the possibility of NAIT and guide
investigations accordingly.
Aetiology
NAIT results from maternal immunisation against foetus-
specific platelet antigens. The exact mechanism underly-
ing maternal sensitisation remains unknown. A prospec-
tive study detected antibodies at 16 weeks of gestation in
primipara primigravida women [3]. The maternal IgG
alloantibodies can cross the placenta as early as the 14th
week of pregnancy. The foetal alloantigens are fully
expressed as early as the 18th week of gestation [11,12]. In
these circumstances, foetal thrombocytopaenia (platelet
counts below 150.109/L) can occur very early during preg-
nancy and there is no spontaneous correction [3].
Although platelets express human leukocyte antigen
(HLA) Class I and ABO blood group antigens at their sur-
face, NAIT is mainly due to alloantibodies directed against
platelet-specific alloantigens. A prospective study analysis
showed that HLA antibodies did not cause thrombocyto-
paenia [14], unless there is an association with neutropae-
nia [15]. Casual observations suggest that NAIT is
sometimes due to ABO incompatibility, although the par-
ticular features of these cases are not well established.
The so-called platelet-specific alloantigens, convention-
ally defined by their exclusive presence on the megakary-
ocyte lineage, have a phenotype frequency that varies
between ethnic groups [16,17]. Since 1990, the Human
Platelet Antigen (HPA) nomenclature has been adopted
[18,19]. The platelet-specific antigen systems have been
numbered chronologically in order of publication, and
the allelic antigens designated alphabetically in order of
frequency in the population: 'a' designating the higher fre-
quency allele, 'b' the lower frequency allele. Polymor-
phism responsible for several of the platelet allotypes has
been identified and a new nomenclature proposed [20].
Among the platelet-specific alloantigens, HPA-1a antigen
is the form most commonly involved in NAIT in Cauca-
sians [21], followed (at much lower frequency) by HPA-
5b [10]. In Asians, NAIT is essentially linked to the HPA-
4 system. Maternal immunisation against 'rare' or 'private'
alloantigens has been reported [22-26].
Retrospective and prospective studies highlighted the
importance of immunogenetic factors in platelet alloim-
munisation. The HLA class II DRB3*0101 allele in moth-
ers could be implicated in anti HPA-1a immunisation [27-
29], whereas anti HPA-5b alloimmunisation was reported
to be associated with a cluster of HLA DR molecules, shar-
ing a particular polymorphic amino-acid sequence at
position 69–70 in the DRβ1 chain [30]. A better under-
standing of the immune response to platelet alloantigens
would allow for a better definition and thus appropriate
management of pregnant women at high risk.Orphanet Journal of Rare Diseases 2006, 1:39 http://www.OJRD.com/content/1/1/39
Page 3 of 6
(page number not for citation purposes)
Diagnostic methods
The first step in the diagnosis is to confirm the isolated
thrombocytopaenia in the newborn, and the absence of
thrombocytopaenia in the mother. The platelet count is
variable, usually as low at birth as <50. 109/L. Anaemia
occurs secondary to bleeding. Platelet immunological
tests require expertise in the field. The therapy should be
started as soon as a provisional diagnosis has been made.
Any difficulties in confirming the diagnosis should not
delay the therapy.
Testing involves the detection of maternal circulating anti-
bodies and identification of the targeted platelet antigen,
with determination of the platelet phenotype and geno-
type of both parents. Antibodies are usually detected with
antigen capture enzyme-linked immunosorbent assay
(ELISA) and the microplate enzyme-linked assay [31].
Molecular techniques are used for genotyping [32]. If the
father is heterozygous for the considered antigen or if the
paternity is uncertain, the platelet typing of the infant
should be performed to confirm the diagnosis. Diagnosis
is certain when parental antigen incompatibility with a
corresponding maternal antibody is demonstrated. The
biological diagnosis is unclear in the absence of such an
antibody (in this case, a repeat testing may substantiate
the diagnosis), or when a new, rare or private antigen is
involved. Diagnosis should be unequivocally established
before a subsequent pregnancy for a better management.
Diagnosis of foetal ICH is made by ultrasonography and
magnetic resonance imaging (MRI).
Differential diagnosis
Careful examination of the infant and consideration of
the maternal history should exclude most of the other
causes of neonatal thrombocytopaenia [33]. However,
NAIT may also be associated with other causes of throm-
bocytopaenia, especially maternal antiplatelet autoimmu-
nity [5]. 
The main other causes of neonatal thrombocytopaenia :
Infection
Bacterial, viral or parasitic infections that may occur in
intensive care units
Disseminated intravascular coagulation
Most often secondary to acute foetal distress or sepsis
Immune destruction
Maternal autoimmunity: autoimmune thrombocyto-






￿ Bone marrow metastases
￿ Congenital leukaemia
￿ Down-regulation of megakaryocytopoiesis during the
course of Rh haemolytic disease or chronic hypoxia
Inherited causes
￿ Constitutional thrombocytopaenia such as Thrombocy-
topaenia associated with Absent Radii (TAR syndrome),
Congenital Amegacaryocytopenia (CAMT), Wiskott-
Aldrich Syndrome, Bernard Soulier Syndrome (BSS)
￿ Thrombocytopaenia due to inherited disorders such as
von Willebrand 2B disease or constitutional deficiency in
ADAMTS 13, leading to Thrombotic Thrombocytopaenic
Purpura.
Genetic counselling
The recurrence of thrombocytopaenia is very high and its
severity usually increases in subsequent pregnancies. The
risk depends on whether the father's platelet genotype is
homozygous or heterozygous for the targeted antigen.
Therefore, in case of heterozygosity or if the paternity is
uncertain, the foetus platelet genotype must be deter-
mined with molecular biology techniques using amnio-
cytes, microvilli or foetal blood sampling. Noninvasive
typing from maternal blood is under investigation.
Platelet typing can be proposed to the sisters of an affected
woman, in order to detect high-risk pregnant women. In
our experience, antenatal management for the first
affected pregnancy depends on the detection of maternal
alloantibodies.
Antenatal diagnosis
In cases of women already identified as at risk of having
or developing HPA alloimmunisation (first child with
NAIT or previous history of NAIT in the family), foetal
genotyping may be performed either on chorionic villi or
on amniotic cells.
Alloimmune thrombocytopaenia can be suspected in case
of foetal ICH. Foetomaternal alloimmune thrombocyto-
paenia presenting antenatally as hydrops foetalis [34] has
also been reported as a complication of foetomaternal
platelet alloimmunisation. Recurrent miscarriages should
be taken into account.Orphanet Journal of Rare Diseases 2006, 1:39 http://www.OJRD.com/content/1/1/39
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When incidental, thrombocytopaenia is discovered by
foetal blood sampling and careful determination of con-
tamination with amniotic fluid should be included. Con-
siderations in the differential diagnosis of foetal
alloimmune thrombocytopaenia include both maternal
and foetal factors, among which thrombocytopaenia in
foetuses small for date with the risk of intraventricular
haemorrhage [35] and foetal hypoxia [36], infection,
chromosomal abnormalities, but associations should not
be ignored. In other causes of thrombocytopaenia,
alloimmunisation should be studied when thrombocyto-
paenia is atypically severe.
Management
Neonatal management
Throughout the thrombocytopaenic period, the infant is
at risk of haemorrhage, especially ICH. Optimal manage-
ment should be initiated on the basis of the clinical situa-
tion, even before the diagnosis has been confirmed by
platelet immunological testing.
Infants with haemorrhages or platelet counts below 30. 109/L during 
the first 24 hours of life
The treatment of choice is the transfusion of platelets,
which will not be destroyed by the maternal antibodies
present in the circulation of the newborn. The mother is
the best donor. After maternal transfusion, the infant's
platelet count usually increases promptly, which itself
argues in favour of alloimmunisation. The maternal plate-
lets must be washed to remove the antiplatelet antibody
and irradiated to prevent graft versus host disease. If the
mother is not available, blood banks can provide HPA1b/
1b donors' platelets, since HPA-1a incompatibility is the
most frequent cause of NAIT. When private or rare platelet
antigens are considered, members of the family can be
genotyped. When compatible platelets are not available or
their delivery is delayed, transfusion of random platelets
with or without intravenous immunoglobulins may be
performed [37]. Intravenous immunoglobulins alone
should not be given in this situation, because of the
delayed onset of their effect (18–24 hours after injection)
[38].
Infants without haemorrhage and a platelet count above 30. 109/L
These cases require close monitoring until an adequate
platelet count is reached. Usually, platelet transfusion is
not necessary, as the platelet count increases rapidly.
Alternatively, in case of severe drop in the platelet count,
the management described above should be considered.
In some cases, intravenous IgG (1g/kg/day for 2 days)
may be used to raise the platelet count.
Outcome and prognosis
The outcome depends on the severity of thrombocytopae-
nia at birth and the promptness of diagnosis and treat-
ment. The need of immediate treatment depends on the
presence of bleeding and the severity of thrombocytopae-
nia. If treatment is required, then it should not be delayed.
In all cases, platelet counts should be closely monitored
until a normal platelet count is obtained. The duration of
the postnatal thrombocytopaenia is usually one to two
weeks, but it may occasionally persist for longer. Radio-
logical evaluation of the head (ultrasonography, MRI) is
required to detect/exclude ICH. In absence of severe
bleeding, the outcome is favourable. When ICH has
occurred, retrospective studies in series of anti HPA-1a
NAIT report a mortality of 10%, and a 20% rate of neuro-
logical sequelae [21,28,39].
Management of subsequent pregnancies
The current management of pregnancies subsequent to a
delivery of an affected child is aimed at preventing ICH
during pregnancy and delivery. Currently, there is no tech-
niques for evaluation the foetal status that do not involve
invasive procedures (i.e. percutaneous umbilical blood
sampling) and do not carry risks. However, in subsequent
pregnancies, maternal anti-HPA-1a antibody titration has
been recently shown to provide indications for the risk of
severely affected foetuses (if measured in standardised
conditions, before any therapy, and determined before 28
weeks of gestation) [40]. The optimal antenatal therapy to
reverse foetal thrombocytopaenia is still a matter of
debate [41-44]. As the results obtained by different teams
in Europe [42] and in the USA [41] do not rely on ran-
domised studies, conclusive recommendations cannot be
provided. There is a consensus that women with high-risk
pregnancies should be followed-up in referral centres
(where they could receive antenatal therapy), with mini-
mal use of invasive procedures. Maternal therapy includ-
ing weekly maternal injection of high doses of
immunoglobulins, with or without corticosteroids, is cur-
rently recommended as the first-line approach. Therapy
can be stratified on the basis of the sibling history of NAIT
[42-44]. Weekly intrauterine platelet transfusions with
antigen negative platelets may be used as salvage therapy
when maternal therapy has failed. Elective Cesaerean sec-
tion is preferred when the foetus is thought to be severely
affected.
Unresolved questions
￿ Mechanism of maternal sensitisation
￿ Modulation of the maternal immunisation
￿ Real incidence of ICH
￿ Best antenatal management
￿ Setting up of the routine antenatal screeningOrphanet Journal of Rare Diseases 2006, 1:39 http://www.OJRD.com/content/1/1/39
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